IQVIA Holdings is closing in on a roughly $1.1 billion takeover of Quotient Sciences, Bloomberg reported, a move that would give the US clinical research group a bigger role in the path from drug development to market.
The number available here is also the limit of what can safely be said. Bloomberg’s summary gives the rough valuation and the broad strategic direction, but not financing terms, timing, or whether the companies have signed anything definitive. In deal language, “closing in on” covers a fair amount of ground between interest and completion.
Even so, $1.1 billion is not the price of a side project. If the transaction happens, IQVIA would be using a large acquisition to extend itself beyond its existing position as a clinical research group and further into the business around bringing medicines to market.
That does not tell us what return IQVIA expects, how Quotient was valued against its revenue or cash flow, or who else might have been involved. It does tell us where management appears willing to put real money rather than presentation slides.
Isla Camilleri
Sophia Borg
Alex de Valletta
Dua Mifsud